ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: PO2008

Psychosis in Adolescence and Young Adulthood with a Kidney Disease Diagnosis in Childhood

Session Information

Category: Pediatric Nephrology

  • 1700 Pediatric Nephrology


  • Dunleavy, Megan, Rowan University Cooper Medical School, Camden, New Jersey, United States
  • McFadden, Christopher B., Rowan University Cooper Medical School, Camden, New Jersey, United States

Advances in medical technology & management continue to improve the lifespan of children with kidney disease; yet, enhanced understanding of this population shows a relative lag. Prior studies examining pediatric kidney disease have repeatedly found neurocognitive deficits in areas of attention, memory, complex cognition, emotion identification and inhibitory control. Such deficits, when considered alongside nervous system injuries resulting from toxin retention and electrolyte aberrations, warrant further investigation. This study seeks to explore for any association among experiences of acute psychosis in adolescence and young adulthood (AYA) and defined history of childhood kidney disease.


To explore this, a retrospective cohort study using electronic medical records (EMR) was conducted. EMR queries were run to identify & categorize study samples into two groups: ICD-coding defined kidney disease vs healthy peer control. Patient data ranging from July 01, 2012, to February 13, 2021, was then queried for episodes of psychosis in both arms.


Results identified 1192 patients as qualifying for study inclusion. Twenty-one (Prevalence= 1.76%; OR= 0.018) patients qualified for inclusion in the kidney disease group. 1171 (Prevalence= 98.24%; OR= 55.76) patients qualified for inclusion in the control group. Data analysis uncovered ten of 1192 (Prevalence= 0.84%; OR= 0.008) cases experienced acute psychosis throughout AYA. One of these ten cases occurred in CKD sample, representing a 4.76% prevalence (OR= 0.05). The remaining nine cases of AYA psychosis occurred in the control sample, representing a prevalence of 0.77% (OR= 0.008).


Preliminary data demonstrate, those with kidney disease had an increased likelihood of 6.46 (CI= 0.78-54.05) times that seen in control sample for development of acute psychosis in AYA. While unable to rule out the observed effect being due to random chance, acknowledgement of the attributions made by restricted data quantities are held. This pilot study, highlights a novel association deserving of further investigation in a large-scale, multicenter format. Establishing a significant association among childhood kidney disease and psychosis in AYA, would therefore prompt initiation of early education efforts aimed to persuade patient self-awareness, and ignite help-seeking mindsets prior to symptom onset.